Allos Therapeutics (ALTH) Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
Tweet Send to a Friend
Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
